APO Research
Talk to an analyst

APO RESEARCH · REPORT

OX40 Receptor Agonist

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global OX40 Receptor Agonist Market Outlook and Growth Opportunities 2026

2 January 2026193 pages

Choose your research edition.

Industry ResearchOX40 Receptor Agonist Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal OX40 Receptor Agonist Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal OX40 Receptor Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal OX40 Receptor Agonist Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal OX40 Receptor Agonist Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global OX40 Receptor Agonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the OX40 Receptor Agonist market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the OX40 Receptor Agonist market include Roche, Pfizer, GlaxoSmithKline, Sorrento Therapeutics, Merk, Incyte, Glenmark, Bristol Myers Squibb and Bioinvent, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global OX40 Receptor Agonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of OX40 Receptor Agonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents OX40 Receptor Agonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the OX40 Receptor Agonist market size, projected growth trends, production technologies, key applications, and end-use industries.

OX40 Receptor Agonist Segment by Company

Roche

Pfizer

GlaxoSmithKline

Sorrento Therapeutics

Merk

Incyte

Glenmark

Bristol Myers Squibb

Bioinvent

AstraZeneca (MedImmune)

Agenus

OX40 Receptor Agonist Segment by Type

Fully Human IgG1 Agonist mAb

Fully Human IgG2 Agonist Ab

Humanised IgG1 Agonist mAb

OX40 Receptor Agonist Segment by Application

Myasthenia Gravis

Psoriasis

Cancers

OX40 Receptor Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global OX40 Receptor Agonist status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions OX40 Receptor Agonist market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify OX40 Receptor Agonist significant trends, drivers, influence factors in global and regions.

6. To analyze OX40 Receptor Agonist competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OX40 Receptor Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of OX40 Receptor Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OX40 Receptor Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the OX40 Receptor Agonist market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global OX40 Receptor Agonist industry.

Chapter 3: Detailed analysis of OX40 Receptor Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of OX40 Receptor Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of OX40 Receptor Agonist in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. OX40 Receptor Agonist Industry Trends Table 2. OX40 Receptor Agonist Industry Drivers Table 3. OX40 Receptor Agonist Industry Opportunities and Challenges Table 4. OX40 Receptor Agonist Industry Restraints Table 5. Global OX40 Receptor Agonist Revenue by Company (US$ Million) & (2021-2026) Table 6. Global OX40 Receptor Agonist Revenue Share by Company (2021-2026) Table 7. Global OX40 Receptor Agonist Sales Volume by Company (K Units) & (2021-2026) Table 8. Global OX40 Receptor Agonist Sales Volume Share by Company (2021-2026) Table 9. Global OX40 Receptor Agonist Average Price (US$/Unit) of Company (2021-2026) Table 10. Global OX40 Receptor Agonist Company Ranking, (2024-2026) & (USD Million) Table 11. Global OX40 Receptor Agonist Key Company Manufacturing Base & Headquarters Table 12. Global OX40 Receptor Agonist Company, Product Type & Application Table 13. Global OX40 Receptor Agonist Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global OX40 Receptor Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Fully Human IgG1 Agonist mAb Table 18. Significant Companies of Fully Human IgG2 Agonist Ab Table 19. Significant Companies of Humanised IgG1 Agonist mAb Table 20. Global OX40 Receptor Agonist Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global OX40 Receptor Agonist Sales Volume by Type (2021-2026) & (K Units) Table 22. Global OX40 Receptor Agonist Sales Volume by Type (2027-2032) & (K Units) Table 23. Global OX40 Receptor Agonist Sales Volume Share by Type (2021-2026) Table 24. Global OX40 Receptor Agonist Sales Volume Share by Type (2027-2032) Table 25. Global OX40 Receptor Agonist Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global OX40 Receptor Agonist Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global OX40 Receptor Agonist Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global OX40 Receptor Agonist Sales Value Share by Type (2021-2026) Table 29. Global OX40 Receptor Agonist Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Myasthenia Gravis Table 31. Significant Companies of Psoriasis Table 32. Significant Companies of Cancers Table 33. Global OX40 Receptor Agonist Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global OX40 Receptor Agonist Sales Volume by Application (2021-2026) & (K Units) Table 35. Global OX40 Receptor Agonist Sales Volume by Application (2027-2032) & (K Units) Table 36. Global OX40 Receptor Agonist Sales Volume Share by Application (2021-2026) Table 37. Global OX40 Receptor Agonist Sales Volume Share by Application (2027-2032) Table 38. Global OX40 Receptor Agonist Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global OX40 Receptor Agonist Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global OX40 Receptor Agonist Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global OX40 Receptor Agonist Sales Value Share by Application (2021-2026) Table 42. Global OX40 Receptor Agonist Sales Value Share by Application (2027-2032) Table 43. Global OX40 Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global OX40 Receptor Agonist Sales by Region (2021-2026) & (K Units) Table 45. Global OX40 Receptor Agonist Sales Market Share by Region (2021-2026) Table 46. Global OX40 Receptor Agonist Sales by Region (2027-2032) & (K Units) Table 47. Global OX40 Receptor Agonist Sales Market Share by Region (2027-2032) Table 48. Global OX40 Receptor Agonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global OX40 Receptor Agonist Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global OX40 Receptor Agonist Sales Value Share by Region (2021-2026) Table 51. Global OX40 Receptor Agonist Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global OX40 Receptor Agonist Sales Value Share by Region (2027-2032) Table 53. Global OX40 Receptor Agonist Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global OX40 Receptor Agonist Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global OX40 Receptor Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global OX40 Receptor Agonist Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global OX40 Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 58. Global OX40 Receptor Agonist Sales Market Share by Country (2021-2026) Table 59. Global OX40 Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 60. Global OX40 Receptor Agonist Sales Market Share by Country (2027-2032) Table 61. Global OX40 Receptor Agonist Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global OX40 Receptor Agonist Sales Value Market Share by Country (2021-2026) Table 63. Global OX40 Receptor Agonist Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global OX40 Receptor Agonist Sales Value Market Share by Country (2027-2032) Table 65. Roche Company Information Table 66. Roche Business Overview Table 67. Roche OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Roche OX40 Receptor Agonist Product Portfolio Table 69. Roche Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Pfizer OX40 Receptor Agonist Product Portfolio Table 74. Pfizer Recent Development Table 75. GlaxoSmithKline Company Information Table 76. GlaxoSmithKline Business Overview Table 77. GlaxoSmithKline OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. GlaxoSmithKline OX40 Receptor Agonist Product Portfolio Table 79. GlaxoSmithKline Recent Development Table 80. Sorrento Therapeutics Company Information Table 81. Sorrento Therapeutics Business Overview Table 82. Sorrento Therapeutics OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Sorrento Therapeutics OX40 Receptor Agonist Product Portfolio Table 84. Sorrento Therapeutics Recent Development Table 85. Merk Company Information Table 86. Merk Business Overview Table 87. Merk OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Merk OX40 Receptor Agonist Product Portfolio Table 89. Merk Recent Development Table 90. Incyte Company Information Table 91. Incyte Business Overview Table 92. Incyte OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Incyte OX40 Receptor Agonist Product Portfolio Table 94. Incyte Recent Development Table 95. Glenmark Company Information Table 96. Glenmark Business Overview Table 97. Glenmark OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Glenmark OX40 Receptor Agonist Product Portfolio Table 99. Glenmark Recent Development Table 100. Bristol Myers Squibb Company Information Table 101. Bristol Myers Squibb Business Overview Table 102. Bristol Myers Squibb OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Bristol Myers Squibb OX40 Receptor Agonist Product Portfolio Table 104. Bristol Myers Squibb Recent Development Table 105. Bioinvent Company Information Table 106. Bioinvent Business Overview Table 107. Bioinvent OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Bioinvent OX40 Receptor Agonist Product Portfolio Table 109. Bioinvent Recent Development Table 110. AstraZeneca (MedImmune) Company Information Table 111. AstraZeneca (MedImmune) Business Overview Table 112. AstraZeneca (MedImmune) OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. AstraZeneca (MedImmune) OX40 Receptor Agonist Product Portfolio Table 114. AstraZeneca (MedImmune) Recent Development Table 115. Agenus Company Information Table 116. Agenus Business Overview Table 117. Agenus OX40 Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Agenus OX40 Receptor Agonist Product Portfolio Table 119. Agenus Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. OX40 Receptor Agonist Distributors List Table 123. OX40 Receptor Agonist Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. OX40 Receptor Agonist Product Image Figure 2. Global OX40 Receptor Agonist Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global OX40 Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 4. Global OX40 Receptor Agonist Sales (2021-2032) & (K Units) Figure 5. Global OX40 Receptor Agonist Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global OX40 Receptor Agonist Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Fully Human IgG1 Agonist mAb Image Figure 10. Fully Human IgG2 Agonist Ab Image Figure 11. Humanised IgG1 Agonist mAb Image Figure 12. Global OX40 Receptor Agonist Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global OX40 Receptor Agonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global OX40 Receptor Agonist Sales Volume Share by Type (2021-2032) Figure 15. Global OX40 Receptor Agonist Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global OX40 Receptor Agonist Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global OX40 Receptor Agonist Sales Value Share by Type (2021-2032) Figure 18. Myasthenia Gravis Image Figure 19. Psoriasis Image Figure 20. Cancers Image Figure 21. Global OX40 Receptor Agonist Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global OX40 Receptor Agonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global OX40 Receptor Agonist Sales Volume Share by Application (2021-2032) Figure 24. Global OX40 Receptor Agonist Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global OX40 Receptor Agonist Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global OX40 Receptor Agonist Sales Value Share by Application (2021-2032) Figure 27. Global OX40 Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global OX40 Receptor Agonist Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global OX40 Receptor Agonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global OX40 Receptor Agonist Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America OX40 Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 32. North America OX40 Receptor Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe OX40 Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 34. Europe OX40 Receptor Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific OX40 Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific OX40 Receptor Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America OX40 Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 38. South America OX40 Receptor Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa OX40 Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa OX40 Receptor Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt OX40 Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. OX40 Receptor Agonist Value Chain Figure 126. Manufacturing Cost Structure Figure 127. OX40 Receptor Agonist Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Fully Human IgG1 Agonist mAb
  • Fully Human IgG2 Agonist Ab
  • Humanised IgG1 Agonist mAb
Applications
  • Myasthenia Gravis
  • Psoriasis
  • Cancers
Companies covered
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Sorrento Therapeutics
  • Merk
  • Incyte
  • Glenmark
  • Bristol Myers Squibb
  • Bioinvent
  • AstraZeneca (MedImmune)
  • Agenus

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global OX40 Receptor Agonist Sales Value (2021-2032)
  4. 1.2.2 Global OX40 Receptor Agonist Sales Volume (2021-2032)
  5. 1.2.3 Global OX40 Receptor Agonist Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 OX40 Receptor Agonist Market Dynamics
  1. 2.1 OX40 Receptor Agonist Industry Trends
  2. 2.2 OX40 Receptor Agonist Industry Drivers
  3. 2.3 OX40 Receptor Agonist Industry Opportunities and Challenges
  4. 2.4 OX40 Receptor Agonist Industry Restraints
3 OX40 Receptor Agonist Market by Company
  1. 3.1 Global OX40 Receptor Agonist Company Revenue Ranking in 2025
  2. 3.2 Global OX40 Receptor Agonist Revenue by Company (2021-2026)
  3. 3.3 Global OX40 Receptor Agonist Sales Volume by Company (2021-2026)
  4. 3.4 Global OX40 Receptor Agonist Average Price by Company (2021-2026)
  5. 3.5 Global OX40 Receptor Agonist Company Ranking (2024-2026)
  6. 3.6 Global OX40 Receptor Agonist Company Manufacturing Base and Headquarters
  7. 3.7 Global OX40 Receptor Agonist Company Product Type and Application
  8. 3.8 Global OX40 Receptor Agonist Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global OX40 Receptor Agonist Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 OX40 Receptor Agonist Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 OX40 Receptor Agonist Market by Type
  1. 4.1 OX40 Receptor Agonist Type Introduction
  2. 4.1.1 Fully Human IgG1 Agonist mAb
  3. 4.1.2 Fully Human IgG2 Agonist Ab
  4. 4.1.3 Humanised IgG1 Agonist mAb
  5. 4.2 Global OX40 Receptor Agonist Sales Volume by Type
  6. 4.2.1 Global OX40 Receptor Agonist Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global OX40 Receptor Agonist Sales Volume by Type (2021-2032)
  8. 4.2.3 Global OX40 Receptor Agonist Sales Volume Share by Type (2021-2032)
  9. 4.3 Global OX40 Receptor Agonist Sales Value by Type
  10. 4.3.1 Global OX40 Receptor Agonist Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global OX40 Receptor Agonist Sales Value by Type (2021-2032)
  12. 4.3.3 Global OX40 Receptor Agonist Sales Value Share by Type (2021-2032)
5 OX40 Receptor Agonist Market by Application
  1. 5.1 OX40 Receptor Agonist Application Introduction
  2. 5.1.1 Myasthenia Gravis
  3. 5.1.2 Psoriasis
  4. 5.1.3 Cancers
  5. 5.2 Global OX40 Receptor Agonist Sales Volume by Application
  6. 5.2.1 Global OX40 Receptor Agonist Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global OX40 Receptor Agonist Sales Volume by Application (2021-2032)
  8. 5.2.3 Global OX40 Receptor Agonist Sales Volume Share by Application (2021-2032)
  9. 5.3 Global OX40 Receptor Agonist Sales Value by Application
  10. 5.3.1 Global OX40 Receptor Agonist Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global OX40 Receptor Agonist Sales Value by Application (2021-2032)
  12. 5.3.3 Global OX40 Receptor Agonist Sales Value Share by Application (2021-2032)
6 OX40 Receptor Agonist Regional Sales and Value Analysis
  1. 6.1 Global OX40 Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global OX40 Receptor Agonist Sales by Region (2021-2032)
  3. 6.2.1 Global OX40 Receptor Agonist Sales by Region: 2021-2026
  4. 6.2.2 Global OX40 Receptor Agonist Sales by Region (2027-2032)
  5. 6.3 Global OX40 Receptor Agonist Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global OX40 Receptor Agonist Sales Value by Region (2021-2032)
  7. 6.4.1 Global OX40 Receptor Agonist Sales Value by Region: 2021-2026
  8. 6.4.2 Global OX40 Receptor Agonist Sales Value by Region (2027-2032)
  9. 6.5 Global OX40 Receptor Agonist Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America OX40 Receptor Agonist Sales Value (2021-2032)
  12. 6.6.2 North America OX40 Receptor Agonist Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe OX40 Receptor Agonist Sales Value (2021-2032)
  15. 6.7.2 Europe OX40 Receptor Agonist Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific OX40 Receptor Agonist Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific OX40 Receptor Agonist Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America OX40 Receptor Agonist Sales Value (2021-2032)
  21. 6.9.2 South America OX40 Receptor Agonist Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa OX40 Receptor Agonist Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa OX40 Receptor Agonist Sales Value Share by Country, 2025 VS 2032
7 OX40 Receptor Agonist Country-level Sales and Value Analysis
  1. 7.1 Global OX40 Receptor Agonist Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global OX40 Receptor Agonist Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global OX40 Receptor Agonist Sales by Country (2021-2032)
  4. 7.3.1 Global OX40 Receptor Agonist Sales by Country (2021-2026)
  5. 7.3.2 Global OX40 Receptor Agonist Sales by Country (2027-2032)
  6. 7.4 Global OX40 Receptor Agonist Sales Value by Country (2021-2032)
  7. 7.4.1 Global OX40 Receptor Agonist Sales Value by Country (2021-2026)
  8. 7.4.2 Global OX40 Receptor Agonist Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt OX40 Receptor Agonist Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt OX40 Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt OX40 Receptor Agonist Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Roche OX40 Receptor Agonist Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer OX40 Receptor Agonist Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline OX40 Receptor Agonist Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Sorrento Therapeutics
  20. 8.4.1 Sorrento Therapeutics Company Information
  21. 8.4.2 Sorrento Therapeutics Business Overview
  22. 8.4.3 Sorrento Therapeutics OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sorrento Therapeutics OX40 Receptor Agonist Product Portfolio
  24. 8.4.5 Sorrento Therapeutics Recent Developments
  25. 8.5 Merk
  26. 8.5.1 Merk Company Information
  27. 8.5.2 Merk Business Overview
  28. 8.5.3 Merk OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merk OX40 Receptor Agonist Product Portfolio
  30. 8.5.5 Merk Recent Developments
  31. 8.6 Incyte
  32. 8.6.1 Incyte Company Information
  33. 8.6.2 Incyte Business Overview
  34. 8.6.3 Incyte OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Incyte OX40 Receptor Agonist Product Portfolio
  36. 8.6.5 Incyte Recent Developments
  37. 8.7 Glenmark
  38. 8.7.1 Glenmark Company Information
  39. 8.7.2 Glenmark Business Overview
  40. 8.7.3 Glenmark OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Glenmark OX40 Receptor Agonist Product Portfolio
  42. 8.7.5 Glenmark Recent Developments
  43. 8.8 Bristol Myers Squibb
  44. 8.8.1 Bristol Myers Squibb Company Information
  45. 8.8.2 Bristol Myers Squibb Business Overview
  46. 8.8.3 Bristol Myers Squibb OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bristol Myers Squibb OX40 Receptor Agonist Product Portfolio
  48. 8.8.5 Bristol Myers Squibb Recent Developments
  49. 8.9 Bioinvent
  50. 8.9.1 Bioinvent Company Information
  51. 8.9.2 Bioinvent Business Overview
  52. 8.9.3 Bioinvent OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bioinvent OX40 Receptor Agonist Product Portfolio
  54. 8.9.5 Bioinvent Recent Developments
  55. 8.10 AstraZeneca (MedImmune)
  56. 8.10.1 AstraZeneca (MedImmune) Company Information
  57. 8.10.2 AstraZeneca (MedImmune) Business Overview
  58. 8.10.3 AstraZeneca (MedImmune) OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca (MedImmune) OX40 Receptor Agonist Product Portfolio
  60. 8.10.5 AstraZeneca (MedImmune) Recent Developments
  61. 8.11 Agenus
  62. 8.11.1 Agenus Company Information
  63. 8.11.2 Agenus Business Overview
  64. 8.11.3 Agenus OX40 Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Agenus OX40 Receptor Agonist Product Portfolio
  66. 8.11.5 Agenus Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 OX40 Receptor Agonist Value Chain Analysis
  2. 9.1.1 OX40 Receptor Agonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 OX40 Receptor Agonist Sales Mode & Process
  6. 9.2 OX40 Receptor Agonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 OX40 Receptor Agonist Distributors
  9. 9.2.3 OX40 Receptor Agonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst